Supplemental Table 3: Bortezomib pharmacokinetic parameters following a single intravenous 1.3 mg/m2 bolus dose in the presence or absence of tabalumab and dexamethasone

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Dosing Conditions** | | | | |
| **Bortezomib (delayed 1 day) with 100 mg tabalumab** |  | **Bortezomib with 100 mg tabalumab** |  | **Bortezomib with 100 mg tabalumab and 20 mg dexamethasone** |
| **N** | 6 |  | 11 |  | 11 |
| **Cmax, ng/mL (% CV)** | 72.8 (262) |  | 148 (212) |  | 162 (61.7) |
| **T1/2, h (range)** | 6.08 (2.87-18.0) |  | 17.0 (3.10-31.2) |  | 16.6 (5.07-72.7) |
| **AUC0-t last, h\*ng/mL (% CV)** | 28.0 (85.7) |  | 50.5 (46.2) |  | 51.4 (41.3) |
| **AUC0-inf, h\*ng/mL (% CV)** | 42.5 (41.8) |  | 66.5 (39.4) |  | 70.1 (45.5) |
| **CL, L/h (% CV)** | 53.6 (47.1) |  | 35.4 (37.9) |  | 34.2 (41.9) |

Abbreviations: AUC0-tlast, area under the serum concentration-time curve from time zero to the time of last measurable plasma concentration; AUC0-inf, area under the serum concentration-time curve from time zero to infinity; CL, systemic clearance; Cmax, maximum plasma concentration; T1/2, elimination half-life.